Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

STAT+: Peptide market poised to explode with new Hims and Noom launches

Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.

STAT+: Peptide market poised to explode with new Hims and Noom launches

Peptide prescriptions are set to become more widely available thanks to recent announcements by telehealth giants Hims & Hers and Noom. These companies have unveiled plans to offer prescriptions for eligible patients, marking a significant development in the peptide market. Synthetic peptides, which consist of short-chain amino acids, were initially popular among bodybuilders but have since gained interest from a diverse range of individuals seeking to enhance their health in various ways.

However, it's important to note that many of these compounded peptides are not approved by the FDA and lack robust clinical evidence in humans. Nevertheless, the Department of Health and Human Services has taken notice of these drugs, with health secretary Robert F. Kennedy Jr. showing particular enthusiasm. Given that Hims and Noom are among the leading players in the telehealth industry, their new offerings represent a major milestone for peptides in the United States.

Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at statnews.com →

More in Finance & Markets

NBT Bancorp: 3 Key Takeaways for Long-Term Investors

Deposit mix improving toward lower-cost funding sources protects margins as the bank pursues regional expansion.

  • NBT Bancorp reported $143M in record net interest income for Q3 2026
  • Diversified business model and expanding noninterest income drove revenue growth
  • Strategic focus on pricing discipline and selective branch expansion ensures long-term success

More from Thursday 19 November →